Steven Wayne Stone

US Patent:

7314713, Jan 1, 2008

Filed:

Sep 3, 2003

Appl. No.:

10/655543

Inventors:

Donna M. Shattuck - Salt Lake City UT, US
Steven Stone - Sandy UT, US
Deanna L. Russell - Salt Lake City UT, US
Victor Abkevich - Salt Lake City UT, US
Steven Hunt - Salt Lake City UT, US

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT
University of Utah - Salt Lake City UT

International Classification:

C12Q 1/68
C12P 19/34
C07H 21/02
C07H 21/04
G01N 33/53

US Classification:

435 6, 435 911, 435 912, 536 243

Abstract:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human obesity and diabetes predisposing gene, specifically the TBC1D1 gene, some mutant alleles of which cause susceptibility to obesity and/or diabetes. More specifically, the invention relates to germline mutations in the TBC1D1 gene and their use in the diagnosis of predisposition to obesity and diabetes. Finally, the invention relates to the screening of the TBC1D1 gene for mutations/alterations, which are useful for diagnosing the predisposition to obesity.

US Patent:

8034564, Oct 11, 2011

Filed:

Apr 26, 2007

Appl. No.:

11/740378

Inventors:

Donna M. Shattuck - Salt Lake City UT, US
Steven Stone - Sandy UT, US
Deanna L. Russell - Salt Lake City UT, US
Victor Abkevich - Salt Lake City UT, US
Steven Hunt - Salt Lake City UT, US

Assignee:

University of Utah Research Foundation - Salt Lake City UT

International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68
C12P 19/34

US Classification:

435 61, 435 911, 435 912, 536 231

Abstract:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human obesity and diabetes predisposing gene, specifically the TBC1D1 gene, some mutant alleles of which cause susceptibility to obesity and/or diabetes. More specifically, the invention relates to germline mutations in the TBC1D1 gene and their use in the diagnosis of predisposition to obesity and diabetes. Finally, the invention relates to the screening of the TBC1D1 gene for mutations/alterations, which are useful for diagnosing the predisposition to obesity.

US Patent:

20120041274, Feb 16, 2012

Filed:

Jul 7, 2011

Appl. No.:

13/177887

Inventors:

Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

A61B 5/00
C12Q 1/68
A61P 35/00
C40B 60/12
C40B 40/06
C07G 15/00
C40B 30/00
C12M 1/34

US Classification:

600300, 506 7, 435 61, 4352872, 506 39, 506 16, 514789, 435 612

Abstract:

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

US Patent:

20120053253, Mar 1, 2012

Filed:

Jul 7, 2011

Appl. No.:

13/178380

Inventors:

Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

A61K 45/00
C40B 30/04
C40B 60/12
A61P 35/00

US Classification:

514789, 506 9, 506 39

Abstract:

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

US Patent:

20130005592, Jan 3, 2013

Filed:

Sep 10, 2010

Appl. No.:

13/394936

Inventors:

Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Darl Flake - Salt Lake City UT, US
Francisco J. Esteva - Houston TX, US
Dihua Yu - Houston TX, US

Assignee:

Board of Regents of the University of Texas System - Austin TX
Myriad Genetics Incorporated - Salt Lake City UT

International Classification:

C40B 30/04
C12Q 1/68
G01N 33/574
C07H 21/04

US Classification:

506 9, 536 2431, 435 611, 435 792, 435 71, 435 723

Abstract:

The invention generally relates to molecular diagnostics, and particularly to molecular markers for cancer therapy response and methods of use thereof.

US Patent:

20130302242, Nov 14, 2013

Filed:

Aug 30, 2011

Appl. No.:

13/819963

Inventors:

Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US

Assignee:

MYRIAD GENETICS, INC. - Salt Lake City UT

International Classification:

C12Q 1/68

US Classification:

424 111, 506 9, 506 39, 506 16

Abstract:

Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.

US Patent:

57892067, Aug 4, 1998

Filed:

Jul 7, 1995

Appl. No.:

8/499787

Inventors:

Sean V. Tavtigian - Salt Lake City UT
Steven Stone - Midvale UT
Ping Jiang - Salt Lake City UT
Alexander Kamb - Salt Lake City UT

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C12P 1934

US Classification:

435 912

Abstract:

The present invention is directed to cloning the ends of genes. Traditionally it has been very difficult to recover the 5' end of a gene. The present invention greatly eases this problem. The invention is a variation on RACE and uses a combination of techniques. Specific genes are purified by using three enrichment steps--1) a polymerase chain reaction, 2) a hybrid capture step, and 3) a second polymerase chain reaction. The inclusion of the hybrid capture step results in a greater enrichment than occurs with RACE. The ends of the gene are retained by use of a novel technique of attaching adaptors at the ends of the nucleic. The 5' end of the gene is conserved by preparing a first strand of cDNA and ligating to this an adaptor which is partially double stranded wherein the overhang or single stranded region of the adaptor is degenerate which allows for a fraction of the adaptor population to hybridize with the first strand of cDNA at the 3' end of the cDNA. This hybridization holds the adaptor in conjunction with the cDNA during the ligation step thereby resulting in a highly efficient ligation. The unique portion of the adaptor is used to design an oligomer to prime the second strand synthesis.

US Patent:

62109499, Apr 3, 2001

Filed:

Nov 30, 1998

Appl. No.:

9/201139

Inventors:

Steven Stone - Midvale UT
Ping Jiang - Salt Lake City UT
Alexander Kamb - Salt Lake City UT

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C07H 2104
C12N 120
C12N 1585
C12N 1563

US Classification:

4352523

Abstract:

The present invention relates to the Multiple Tumor Suppressor (MTS) genes in mice, their expression products, and their homology to the human MTS genes. The human MTS genes are involved in human cancers. The invention is further related to the use of the MTS genes in the therapy, diagnosis and prognosis of human cancer. The invention further relates to mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.